<DOC>
	<DOCNO>NCT00002225</DOCNO>
	<brief_summary>The purpose study see safe effective give efavirenz plus stavudine plus didanosine HIV-infected patient never receive anti-HIV treatment .</brief_summary>
	<brief_title>A Study Efavirenz Combination With Stavudine Didanosine</brief_title>
	<detailed_description>Patients give combination treatment efavirenz , stavudine , didanosine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection plasma HIVRNA great equal 10,000 copies/ml . A life expectancy least 12 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Current bilateral peripheral neuropathy great equal Grade 2 . Any clinically significant laboratory finding obtain screen evaluation ( see laboratory value ) . Any clinically significant disease ( HIV infection ) clinically significant finding screen medical history physical examination . Any malignancy require systemic therapy . Proven suspect acute hepatitis due cause . Recurrent episodes moderate severe diarrhea , vomit last 4 day within 3 month prior dose . Active AIDSdefining opportunistic infection disease . Concurrent Medication : Excluded : Astemizole , cisapride , clarithromycin , ketoconazole , itraconazole , midazolam , rifabutin , rifampin , terfenadine , thalidomide , triazolam , vincristine , zalcitabine . Patients follow prior condition exclude : History acute chronic pancreatitis . Life expectancy le 12 month . Difficulty swallow capsules/tablets . Hypersensitivity component formulation efavirenz , stavudine , didanosine . Prior Medication : Excluded : Any experimental drug within 30 day introduce study treatment . Vaccination within 3 week screen visit . Interferon start within 30 day initiate study treatment . Prior antiretroviral therapy . Risk Behavior : Excluded : Current alcohol illicit drug use would interfere compliance dose schedule protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>efavirenz</keyword>
</DOC>